Intimation of closure of trading window from April 1, 2026 to May 16, 2026 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2026.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences (formerly Glenmark Life Sciences) has announced a Board meeting on May 14, 2026 to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026, and to recommend any dividend. The company has closed its trading window for designated persons from April 1, 2026 to May 16, 2026. This closure is a standard preventive measure under SEBI's Insider Trading Regulations, preventing designated persons from trading in company shares while in possession of unpublished financial information ahead of the results announcement.
This is a routine corporate governance filing. The trading window closure is a compliance requirement to protect investors from potential insider trading. Shareholders should note that results are expected around May 14, 2026, and normal trading for insiders resumes after May 16, 2026.